Purpose: To review the current literature describing cases of fungal keratitis and endophthalmitis after Boston keratoprosthesis (KPro) implantation and to characterize the antifungal activity of 0.01% hypochlorous acid against medically relevant fungi.
T he Boston keratoprosthesis (KPro) has been used in the management of patients with severe corneal disease in which success with traditional penetrating keratoplasty is unlikely. 1 Prophylactic use of broad-spectrum antibiotics, such as the combination of polymyxin B and trimethoprim or a fluoroquinolone, with the addition of vancomycin (14 mg/mL with 0.005% benzalkonium chloride) in high-risk patients, has dramatically reduced the incidence of bacterial endophthalmitis. 2 However, it has also increased the risk of fungal colonization and infections. 3 Fungal colonization of the associated soft contact lens presents as small, white, mulberry-shaped deposits (Fig. 1A) . Culture and replacement of the lens is advisable in addition to a course of topical antifungal, for example, amphotericin B 0.15% twice daily for several weeks. When active fungal keratitis (white sheen around optic stem, Fig. 1B ) or endophthalmitis is identified clinically or confirmed with corneal or vitreous cultures, a combination of topical and systemic/intravitreal antifungal is indicated and adjusted according to fungal Gram staining and culture results.
Despite the lifelong risk of fungal infections in KPro patients, an optimal fungal prophylaxis agent and regime have not yet been defined. Long-term success of the KPro depends on the choice of antimicrobial prophylaxis and patient compliance. An ideal agent should be widely available, inexpensive, and highly efficacious while minimizing ocular surface irritation and toxicity. Fungal prophylaxis is not routinely administered but may benefit at-risk patients, such as those living in endemic areas, agricultural workers, or patients with a history of fungal infection or recurrent cultureproven colonization of their soft contact lens. Current recommendations for fungal prophylaxis include brief periodic bursts of topical antifungal agents, although these are not evidence based. Amphotericin B 0.15%, or natamycin 5%, twice daily for 1 to 2 weeks every 3 months are options, although high cost and the lack of availability remain barriers to patient compliance, especially in developing countries where the need for prevention of fungal infections is most pressing. 4 Monthly administration of 5% povidone-iodine at each clinic visit or during contact lens exchange to prevent fungal colonization has also been described, but corneal toxicity and patient discomfort with more frequent administration limits its long-term use. 5, 6 There is an unmet need for novel antimicrobial prophylaxis agents to prevent fungal colonization and infections in KPro patients.
In this study, we review the literature to summarize reported cases of fungal infections (keratitis and endophthalmitis) in KPro patients and characterize infection rates, causative organisms, treatments, and outcomes. We also report the in vitro antifungal activity of 0.01% hypochlorous acid against representative mold and yeast species known to cause ocular infections.
MATERIALS AND METHODS

Literature Review
A review of the literature from January 2001 to April 2015 was performed using PubMed and the search terms "Boston Keratoprosthesis" as well as "fungal," "bacterial," or "infectious" in combination with "keratitis," or "endophthalmitis." Cases of fungal keratitis or endophthalmitis after KPro surgery were identified by review of the title and abstracts of search results. Infection rates were recorded as fungal infections per patient-year of follow-up if cumulative follow-up months were reported.
In Vitro Antifungal Activity of 0.01%
Hypochlorous Acid
A time kill assay based on the Clinical and Laboratory Standards Institute method for testing fungal species was performed at the Massachusetts Eye and Ear Infirmary microbiology laboratory. 7 Fungal species tested included 5 mold (Acremonium kiliense strain ATCC 14491, Aspergillus flavus strain ATCC 204304, Aspergillus fumigatus strain ATCC MYA-3626, Fusarium solani strain ATCC MYA-3636, and Mucor indicus strain ATCC MYA-4678) and 2 yeast species (Candida albicans strain ATCC 24433 and Candida parapsilosis strain ATCC 22019).
Fungal inocula were prepared as follows: fungi were grown on Sabouraud dextrose agar plates for 48 to 72 hours at 30°C. Plates growing molds were flooded with 2 mL normal saline (0.9% NaCl in water), and a suspension of conidia was prepared by scrubbing the plate with an inoculation loop. Hyphae and other large fragments were allowed to settle, and conidia were transferred to a new tube and serial-diluted in normal saline to obtain a final concentration of 5 · 10 6 to 5 · 10 7 colony-forming units per milliliter. For yeasts, a loop-full of cells was suspended in 0.5 mL normal saline and serialdiluted as described above. All work with yeasts and molds was performed in a Class II Biosafety Cabinet.
The in vitro time kill assay was performed by exposing 2 mL of the conidia or cell suspension to 18 mL of normal saline (negative control) or 18 mL of 0.01% hypochlorous acid (Avenova; NovaBay Pharmaceuticals, Emeryville, CA). After 1 minute, 180 mL of Dey-Engley neutralizing broth (D/E broth; Fluka) was added to inactivate the hypochlorous acid. Then, 20 mL of sample was 10-fold serially diluted in 180 mL of D/E broth up to a final dilution of 1:10,000,000. Plates were incubated at 30°C for 2 to 4 days, depending on the growth rate of the organism. Each species was tested in triplicate using 3 independent cell or conidia suspensions. Tests with hypochlorous acid were performed in duplicate (technical duplicates). After 2 to 4 days at 30°C, each well of the microtiter dish was scored for the presence of fungal growth. D/E broth without fungal growth was clear and purple because of the presence of a pH indicator dye. Wells were scored as positive for fungal growth if they showed visual turbidity or fungal mycelia. Depending on the species, a change in media color from purple to yellow was indicative of metabolic activity and aided in scoring. Samples that were exposed to saline served as negative controls and were used to calculate the concentration of cells or conidia in the initial inoculum. A reduction in viable cells or conidia by 4 log 10 units was reported as a 99.99% kill rate.
RESULTS
Literature Review
Fifteen publications, consisting predominantly of retrospective case series, were identified. Table 1 summarizes cases of published fungal keratitis or endophthalmitis in KPro patients between January 2001 and April 2015. 3, 5, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Rates of infection vary from 0.009 to 0.02 fungal infections per patient-year of follow-up. 3, 15 In the largest single-surgeon series reported (291 eyes), the incidence of fungal endophthalmitis was 2.4% during a 10-year period. 19 Fungal organisms are responsible for approximately 10% of all reported KPro endophthalmitis cases in the literature. 17 Reports originating from developing countries were scarce and consisted mostly of case series from Brazil and India. 13, 14, 20 Causative organisms included both yeasts (Candida albicans, Candida parapsilosis, Candida glabrata, and Candida famata) and molds (Fusarium spp., Aspergillus spp., and Alternaria spp.). Reported antibiotic prophylaxis at the time of diagnosis included predominantly fourth-generation fluoroquinolone or vancomycin monoprophylaxis, or a combination of fluoroquinolone and vancomycin. Vancomycin use and contact lens wear were identified as significant risk factors for the development of fungal infections in some series 3 but not in others. 15 Treatment regimes included stopping steroids, increasing antibiotic frequency, and the addition of topical antifungal agents, amphotericin B, natamycin, or voriconazole, for fungal keratitis. Advancing fungal keratitis or endophthalmitis was supplemented with intravitreal and/or systemic antifungals including oral voriconazole, itraconazole, and fluconazole. KPro exchange or explantation was required in progressive cases despite maximal medical therapy. 3, 14, 15 If found early and treated appropriately, most patients retained good vision after cases of fungal infection. 3, 15 This was not the case with reports from developing countries, including India and Brazil, where outcomes were poor, often resulting in phthisis with no useful vision or evisceration. 14, 20 A search for a potential novel antimicrobial agent to prevent fungal infections in KPro patients identified hypochlorous acid (HOCl), whose application in wound treatment was described 100 years ago. 21 Although the antibacterial spectrum of HOCl has been well characterized previously, its activity against fungal species frequently isolated from ocular infections remains to be determined.
Hypochlorous Acid
Preliminary results showed that 0.01% hypochlorous acid reduced the number of viable conidia of Acremonium kiliense, Aspergillus flavus, Aspergillus fumigatus, Fusarium solani, and Mucor indicus by at least 99% within 15 seconds. After a 1minute incubation period, antifungal activity was 99.9% or better, which did not change when the exposure time was extended to 4 minutes. Therefore, all fungal isolates were tested for 1 minute in the presence of 0.01% hypochlorous acid. Table 2 shows the kill rate or percent reduction of viable cells or conidia (spores) of mold and yeast species tested after exposure to 0.01% hypochlorous acid for 1 minute. At an inoculum concentration of 5 · 10 6 to 5 · 10 7 colony-forming units per milliliter, the minimal fold reductions in viable cells or conidia was 99.99% or better for all mold and yeast species tested. In some species, kill rates of $99.999% were observed. These results highlight the substantial fungicidal activity of 0.01% hypochlorous acid that takes place within 60 seconds. When 0.01% hypochlorous acid was tested at a cell or conidia density exceeding the recommended concentration, the reduction in viable cells ranged from 90% to 99.9999% (data not shown).
DISCUSSION
Although bacterial endophthalmitis has dramatically declined since the introduction of vancomycin to the prophylactic antibiotic regimen in 1999, the rate of fungal colonization and infections in KPro patients has subsequently increased. The prolonged use of broad-spectrum antibiotics, steroids, and therapeutic contact lenses has led to increased rates of fungal infections. Treatment and prophylaxis of fungal infections in KPro patients is complicated by the fact that fungal colonization fluctuates over time, positive cultures cannot predict infection, and there is no consensus on a longterm antifungal prophylaxis. 3 From our review of the literature, we found that the proportion of eyes developing fungal infections varies greatly among published reports and is difficult to compare across studies given inconsistent reporting of follow-up periods. The best estimate is obtained from a single-surgeon series spanning over 20 years, in which fungal endophthalmitis increased from 0% between 1990 and 1999 to 2.4% between 2000 and 2010. 19 This shift was coincident with the introduction of vancomycin and therapeutic soft contact lens wear. Although there are few case reports 14, 20 originating from developing countries, given the endemic nature of fungal organisms in these tropical humid environments, we surmise the true incidence of fungal infections would be higher than those reported in the United States. Reported outcomes for KPro patients in the Western hemisphere are good, as early recognition and treatment of indolent fungal infections can limit visual loss. However, a subset of these patients will have carrier corneal tissue that remains prone to melting and cure often involves months of antifungal treatment. 15 In contrast, for patients in the developing world, outcomes are uniformly poor and often related to limited medical and economic resources coupled with patient noncompliance. An effective, safe, and inexpensive antifungal prophylaxis is needed in this setting.
In our study, we addressed this need by testing the in vitro activity of hypochlorous acid against mold and yeast species known to cause ocular infections and which also pose a threat to KPro patients as identified in our literature review. Avenova (NovaBay Pharmaceuticals) is a solution of 0.01% hypochlorous acid (HOCl) in unbuffered saline that has been cleared by the Food and Drug Administration as an adjunct treatment for blepharitis. In an in vitro time kill assay, the solution was rapidly fungicidal and sporicidal within 60 seconds for all mold and yeast species tested. In temperate climates, yeasts predominate, whereas in hot and humid environments, such as India, molds are more common. This pattern was reflected in the fungal species isolated from KPro patients with Candida spp., including C. parapsilosis, being among the most common causative organisms responsible for fungal infections in the Western hemisphere (Table 1) . C. parapsilosis characteristically adheres to prosthetic materials with a particular propensity to cause infections in KPro patients. In our in vitro assay, hypochlorous acid reduced all viable cells of C. parapsilosis by more than 4 log 10 units (.99.99% kill rate) in 60 seconds. Mold species, such as Aspergillus and Fusarium, were also frequent causes of ocular infections, especially in tropical climates, and hypochlorous acid was shown to reduce viable conidia by $99.99% as well.
An ideal antifungal prophylaxis agent would be rapidly fungicidal and sporicidal, broad spectrum, and relatively inexpensive with proven in vitro and in vivo efficacy and a favorable side effect profile. In our study, hypochlorous acid, 0.01%, effectively eliminated all molds (including Fusarium and Aspergillus) and yeasts (Candida spp.) tested, with fungicidal activity observed in as early as 15 seconds. This rapid fungicidal and sporicidal activity is a significant advantage over traditional antifungal treatments that require hours or even days to show activity and may not be active against conidia (spores). Unlike some antifungal agents that are active against certain species but not others, hypochlorous acid showed rapid and potent activity against all species tested, including the genera Acremonium, Aspergillus, Fusarium, Mucor, and Candida. This broad spectrum of activity makes hypochlorous acid an attractive candidate for a global antifungal prophylaxis agent, especially in developing countries. However, to confirm the candidacy of hypochlorous acid as a topical prophylactic antifungal, concerns regarding its ocular surface and potential intraocular toxicity must be addressed. In addition, a subset of KPro patients, such as those with Stevens-Johnson syndrome/toxic epidermal necrolysis, mucous membrane pemphigoid, and chemical burn patients have already compromised ocular surfaces with an increased risk of corneal melting; therefore, we must ensure that topical agents cannot diffuse into the eye around the KPro stem. 22 Hypochlorous acid is a naturally occurring antimicrobial agent produced by neutrophils and monocytes as part of our body's innate immune response. In vitro testing of HOCl against mouse dermal fibroblasts showed that a single 10-fold dilution was comparable to the cytotoxicity observed in unexposed control fibroblasts. 23 In addition, its topical use as a wound cleanser in humans has been reported without adverse events or systemic toxicity. 24 Because the active ingredient in HOCl is reactive, not persistent, and even further diluted by the tear film, we believe the potential for ocular surface and intraocular toxicity is low. To address these questions, we are currently planning a clinical trial in KPro patients to monitor the effects of daily application of 0.01% hypochlorous acid to the eyelid margin on both the ocular surface and intraocular environment. In the long run, prophylactic therapy should be tailored with both patient and regional factors in mind. Precisely which patients should receive chronic prophylaxis, as well as prophylaxis dosing and duration, will require further evaluation.
